Market Closed -
Nyse
04:00:02 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.8601
USD
|
+10.60%
|
|
-0.55%
|
-49.11%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,355
|
2,856
|
3,334
|
1,721
|
-
|
-
|
Enterprise Value (EV)
1 |
10,827
|
1,540
|
2,390
|
1,045
|
1,172
|
1,181
|
P/E ratio
|
-6.16
x
|
-1.35
x
|
-3.67
x
|
-2.69
x
|
-3.17
x
|
-4.37
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
39.4
x
|
5.98
x
|
13.3
x
|
7.71
x
|
5.56
x
|
4.07
x
|
EV / Revenue
|
34.5
x
|
3.22
x
|
9.5
x
|
4.68
x
|
3.78
x
|
2.79
x
|
EV / EBITDA
|
-102
x
|
-8.91
x
|
-6.72
x
|
-2.58
x
|
-3.63
x
|
-4.76
x
|
EV / FCF
|
-34,887,787
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
7.51
x
|
1.84
x
|
3.08
x
|
2.77
x
|
3.91
x
|
9.56
x
|
Nbr of stocks (in thousands)
|
1,486,734
|
1,689,647
|
1,972,725
|
2,001,315
|
-
|
-
|
Reference price
2 |
8.310
|
1.690
|
1.690
|
0.8601
|
0.8601
|
0.8601
|
Announcement Date
|
3/28/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
313.8
|
477.7
|
251.5
|
223.2
|
309.8
|
422.8
|
EBITDA
1 |
-
|
-106
|
-172.8
|
-355.4
|
-404.8
|
-322.9
|
-248.3
|
EBIT
1 |
-
|
-1,828
|
-2,209
|
-864.4
|
-653.6
|
-545.1
|
-445.4
|
Operating Margin
|
-
|
-582.62%
|
-462.41%
|
-343.76%
|
-292.85%
|
-175.97%
|
-105.35%
|
Earnings before Tax (EBT)
1 |
-
|
-1,838
|
-2,121
|
-892.9
|
-631.1
|
-534.4
|
-452.7
|
Net income
1 |
-126.6
|
-1,830
|
-2,105
|
-892.9
|
-631
|
-534.3
|
-410.1
|
Net margin
|
-
|
-583.12%
|
-440.63%
|
-355.08%
|
-282.71%
|
-172.48%
|
-97%
|
EPS
2 |
-16.18
|
-1.350
|
-1.250
|
-0.4600
|
-0.3200
|
-0.2717
|
-0.1967
|
Free Cash Flow
|
-
|
-310.3
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-98.89%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/14/21
|
3/28/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
77.61
|
148.5
|
168.4
|
144.6
|
66.4
|
98.28
|
80.7
|
80.57
|
55.43
|
34.76
|
46.04
|
53.22
|
58.71
|
65.18
|
66.27
|
EBITDA
1 |
-17.98
|
0.562
|
-1.951
|
-23.32
|
-69.63
|
-80.2
|
-100
|
-75.46
|
-83.82
|
-95.77
|
-92.11
|
-89.94
|
-89.43
|
-87.39
|
-86.53
|
EBIT
1 |
-26.67
|
-1,685
|
-674.5
|
-646.9
|
-653
|
-234.5
|
-215.7
|
-184.2
|
-286.4
|
-178.1
|
-168.5
|
-164.4
|
-162.7
|
-163.4
|
-146.5
|
Operating Margin
|
-34.37%
|
-1,134.55%
|
-400.53%
|
-447.32%
|
-983.49%
|
-238.6%
|
-267.34%
|
-228.57%
|
-516.68%
|
-512.49%
|
-365.91%
|
-308.92%
|
-277.17%
|
-250.72%
|
-221.08%
|
Earnings before Tax (EBT)
1 |
-102.6
|
-1,606
|
-592.8
|
-670.6
|
-669.1
|
-188.9
|
-204.9
|
-173.2
|
-302.9
|
-211.9
|
-169.4
|
-167.4
|
-166.6
|
-164.9
|
-154
|
Net income
1 |
-101.9
|
-1,601
|
-590.5
|
-668.8
|
-669.1
|
-176.5
|
-205
|
-173.3
|
-302.9
|
-211.7
|
-162.2
|
-157.3
|
-157.1
|
-159.7
|
-153.8
|
Net margin
|
-131.27%
|
-1,077.93%
|
-350.65%
|
-462.48%
|
-1,007.64%
|
-179.62%
|
-253.98%
|
-215.12%
|
-546.44%
|
-609.1%
|
-352.34%
|
-295.52%
|
-267.6%
|
-245.06%
|
-232.09%
|
EPS
2 |
-0.0800
|
-1.050
|
-0.3700
|
-0.4100
|
-0.4100
|
-0.1000
|
-0.1100
|
-0.0900
|
-0.1600
|
-0.1100
|
-0.0833
|
-0.0817
|
-0.0783
|
-0.0767
|
-0.0833
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/28/22
|
5/16/22
|
8/15/22
|
11/14/22
|
3/1/23
|
5/10/23
|
8/9/23
|
11/8/23
|
2/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
1,528
|
1,316
|
944
|
676
|
550
|
540
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-310
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-186%
|
-130%
|
-63%
|
-68.8%
|
-104%
|
-125%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
1.110
|
0.9200
|
0.5500
|
0.3100
|
0.2200
|
0.0900
|
Cash Flow per Share
2 |
-
|
-0.1900
|
-0.1400
|
-0.1500
|
-0.1900
|
-0.1300
|
-
|
Capex
|
-
|
56.5
|
52.3
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
18.01%
|
10.94%
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/14/21
|
3/28/22
|
3/1/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
0.8601
USD Average target price
1.92
USD Spread / Average Target +123.23% Consensus |
1st Jan change
|
Capi.
|
---|
| -49.11% | 1.72B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|